Nothing Special   »   [go: up one dir, main page]

CA2844805A1 - Methods and compositions for the treatment and diagnosis of breast cancer - Google Patents

Methods and compositions for the treatment and diagnosis of breast cancer Download PDF

Info

Publication number
CA2844805A1
CA2844805A1 CA2844805A CA2844805A CA2844805A1 CA 2844805 A1 CA2844805 A1 CA 2844805A1 CA 2844805 A CA2844805 A CA 2844805A CA 2844805 A CA2844805 A CA 2844805A CA 2844805 A1 CA2844805 A1 CA 2844805A1
Authority
CA
Canada
Prior art keywords
cancer
expression
breast
subject
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2844805A
Other languages
English (en)
French (fr)
Inventor
Karen Chapman
Joseph Wagner
Michael West
Jennifer Lorrie KIDD
Maria J. Prendes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncocyte Corp
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of CA2844805A1 publication Critical patent/CA2844805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2844805A 2011-08-16 2012-08-16 Methods and compositions for the treatment and diagnosis of breast cancer Abandoned CA2844805A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524170P 2011-08-16 2011-08-16
US61/524,170 2011-08-16
US201161553706P 2011-10-31 2011-10-31
US61/553,706 2011-10-31
PCT/US2012/051235 WO2013025952A2 (en) 2011-08-16 2012-08-16 Methods and compositions for the treatment and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
CA2844805A1 true CA2844805A1 (en) 2013-02-21

Family

ID=47715702

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2844805A Abandoned CA2844805A1 (en) 2011-08-16 2012-08-16 Methods and compositions for the treatment and diagnosis of breast cancer

Country Status (9)

Country Link
US (1) US20140235486A1 (zh)
EP (1) EP2744917A4 (zh)
JP (2) JP2014525240A (zh)
KR (1) KR20140057331A (zh)
CN (1) CN104080924A (zh)
AU (1) AU2012296405B2 (zh)
CA (1) CA2844805A1 (zh)
HK (1) HK1199290A1 (zh)
WO (1) WO2013025952A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909337B1 (en) 2012-10-17 2019-01-09 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US20160018399A1 (en) * 2013-03-08 2016-01-21 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation
AU2015277059B2 (en) * 2014-06-18 2021-06-17 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
US9784743B2 (en) 2015-06-22 2017-10-10 Rhode Island Hospital, A Lifespan-Partner Collagens as markers for breast cancer treatment
CN105255927B (zh) * 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
WO2017061953A1 (en) * 2015-10-05 2017-04-13 Agency For Science, Technology And Research Invasive ductal carcinoma aggressiveness classification
AU2016369603A1 (en) 2015-12-18 2018-07-05 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US20210301289A1 (en) * 2016-07-29 2021-09-30 Roger L. Kaspar Methods of treating osmidrosis
CN109422810A (zh) * 2017-08-24 2019-03-05 孙立春 全人源或人源化bombesin受体GRPR单克隆抗体药物或诊断试剂的开发及应用
US20200063202A1 (en) * 2018-04-25 2020-02-27 Juneau Biosciences, L.L.C. Methods of using genetic markers associated with endometriosis
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US20210199660A1 (en) * 2019-11-22 2021-07-01 10X Genomics, Inc. Biomarkers of breast cancer
CN112501303A (zh) * 2020-12-14 2021-03-16 西北工业大学 分子标志物col11a1及其在乳腺癌药物中的应用
JP2024535694A (ja) * 2021-09-10 2024-10-02 グレイル インコーポレイテッド 生体液中の標的分子の分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1410011E (pt) * 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20070218512A1 (en) * 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
AU2008264893A1 (en) * 2007-04-16 2008-12-24 Inserm- Institut National De La Sante Et De La Recherche Medicale Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008132167A2 (en) * 2007-04-26 2008-11-06 Dublin City University Diagnostic, prognostic and/or predictive indicators of breast cancer
EP2163649A1 (en) * 2008-09-11 2010-03-17 Fédération Nationale des Centres de Lutte Contre le Cancer Molecular classifier for evaluating the risk of metastasic relapse in breast cancer
AU2010302955A1 (en) * 2009-10-01 2012-05-17 Chipdx Llc System and method for classification of patients
CN101701220A (zh) * 2009-11-13 2010-05-05 南开大学 一种乳腺癌相关基因c10rf64及其应用
AU2010321829B2 (en) * 2009-11-23 2015-07-30 Genomic Health, Inc. Methods to predict clinical outcome of cancer
US20110217297A1 (en) * 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles

Also Published As

Publication number Publication date
AU2012296405B2 (en) 2016-03-17
EP2744917A4 (en) 2015-10-14
WO2013025952A3 (en) 2014-05-08
US20140235486A1 (en) 2014-08-21
WO2013025952A2 (en) 2013-02-21
EP2744917A2 (en) 2014-06-25
KR20140057331A (ko) 2014-05-12
JP2019030300A (ja) 2019-02-28
JP2014525240A (ja) 2014-09-29
CN104080924A (zh) 2014-10-01
AU2012296405A1 (en) 2014-02-27
HK1199290A1 (zh) 2015-06-26

Similar Documents

Publication Publication Date Title
AU2012296405B2 (en) Methods and compositions for the treatment and diagnosis of breast cancer
US20140206574A1 (en) Methods and Compositons for the Treatment and Diagnosis of Cancer
US20140221244A1 (en) Methods and Compositions for the Treatment and Diagnosis of Colorectal Cancer
JP2018102299A (ja) 膀胱癌の処置および診断のための方法および組成物
US20140141996A1 (en) Methods and Compositions for the Treatment and Diagnosis of Cancer
US20150018235A1 (en) Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
CA2840472A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
US20140315743A1 (en) Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
WO2013106747A2 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2017181163A2 (en) Methods and compositions for detection and diagnosis of breast cancer
US20130295581A1 (en) Methods and Compositions for the Treatment and Diagnosis of Breast Cancer
WO2015013455A2 (en) Methods and compositions for the treatment and diagnosis of cancer
WO2017214189A1 (en) Methods and compositions for detection and diagnosis of bladder cancer
CN106811548B (zh) Slc38a4作为结肠腺癌的诊治靶标
WO2019074920A1 (en) METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170811

FZDE Discontinued

Effective date: 20200831